No, tirzepatide should not be discontinued after reaching target weight—obesity requires long-term treatment to maintain weight loss and prevent regain.
Discontinuing tirzepatide after achieving target weight leads to significant weight regain, and the medication should be considered chronic therapy for obesity management 1, 2.
Evidence for Continued Treatment
The most robust evidence comes from the SURMOUNT-MAINTAIN trial 2, which directly addressed this question. After patients achieved weight loss with tirzepatide (mean -21.9% at week 60), those who continued the medication maintained their weight loss (-21.9% total at week 112), while those switched to placebo regained substantial weight (only -9.9% total at week 112). This represents approximately 12% weight regain when stopping the medication.
The weight regain after discontinuation is proportional to the amount originally lost—a systematic review found that patients who discontinued semaglutide/tirzepatide regained an average of 9.69 kg 1. This pattern occurs regardless of lifestyle interventions, reinforcing that obesity is a chronic disease requiring ongoing pharmacotherapy.
Clinical Implications
If Discontinuation is Being Considered:
Dose reduction may be preferable to complete discontinuation: The SURMOUNT-MAINTAIN trial showed that reducing to 5 mg tirzepatide maintained -16.6% weight loss (versus -9.9% with placebo), providing a middle-ground option 2
Real-world data shows variable outcomes: Approximately two-thirds of patients maintain stable weight or continue losing in the 6 months after their last prescription, though this may reflect continued medication use or other interventions 3
Exercise counseling appears protective: Patients with documented exercise counseling showed less weight regain (26.2% vs 14.7%, p=0.04) 3
Common Pitfalls:
The primary reason for discontinuation in clinical practice is cost/insurance issues (47.6%), not achievement of weight goals 4. Only 2.4% discontinued due to unsatisfactory weight loss, and 14.6% due to intolerable side effects 4. This highlights that most discontinuations are involuntary rather than planned.
Treatment Framework
For patients at target weight on tirzepatide:
- Continue at maximum tolerated dose for sustained weight maintenance 2
- If cost is prohibitive: Consider dose reduction to 5 mg rather than complete discontinuation 2
- If discontinuation is unavoidable: Intensify lifestyle interventions, particularly structured exercise programs 3
- Monitor closely: If weight regain exceeds 50% of lost weight, strongly consider reinitiating therapy 2
For patients with obesity at moderate-to-high cardiovascular risk, the 2025 BMJ guideline emphasizes that tirzepatide should not replace medications with proven cardiovascular benefits (SGLT-2 inhibitors or GLP-1 receptor agonists), and if switching from a GLP-1 agonist to tirzepatide, an SGLT-2 inhibitor should be initiated or continued 5.
Obesity is a chronic disease requiring long-term management—just as we don't discontinue antihypertensives when blood pressure normalizes, weight-loss medications should be continued to maintain therapeutic benefits 1, 2.